Thermo Fisher is the world's lab supply superstore, selling everything from pipettes to gene sequencers to drug manufacturing services for scientists and pharma companies.
Money comes from recurring consumables and services across four segments, with gross margins around 40% and net margins near 15% on USD 44.56B annual revenue.
Customers stick with Thermo Fisher because switching disrupts validated lab workflows, and its scale in distribution and biopharma services is hard for Danaher or Agilent to replicate quickly. moat_level: solid
Hold (sector percentile 33) — value B-, growth B-, profitability C+, momentum B, revisions C+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Institutional quarterly holding disclosure shows Argent Capital significantly reduced its TMO position
Continuation of Q2 earnings line with new product launch reinforcing growth narrative
Beat on profit and revenue; sales rose across all business segments
None yet
None yet
Thermo Fisher Scientific is a favorite among hedge funds and mutual funds, according to Goldman Sachs analysis, suggesting a positive outlook based on past performance.
Main discussion
Goldman Sachs analyzed roughly $10 trillion in hedge fund and mutual fund positioning. Their shared favorites heading into Q3: 1. $BA 2. $COF 3. $MA 4. $SPCX 5. $TMO 6. $V This basket has returned 29% YTD, outperforming the equal-weight S&P 500 by 13 percentage points. These stoc
$TMO Same repeatable setup over and over. https://t.co/v2kBcYxIIu
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
